Literature DB >> 20736225

Is an involved circumferential resection margin following oesphagectomy for cancer an important prognostic indicator?

Omar A Khan1, David Cruttenden-Wood, Simon K Toh.   

Abstract

A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was whether an involved circumferential resection margin (CRM) following oesophagectomy for cancer is an independent predictor of poor long-term survival. Six hundred and fourteen papers were found using the reported search, of which seven represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group, study type, relevant outcomes and results of these papers are tabulated. Of these studies, four were conducted on patients who predominantly did not receive preoperative chemotherapy and showed conflicting results as to the prognostic significance of CRM involvement. However, three later studies conducted on patients who predominantly did receive preoperative chemotherapy showed that CRM involvement to be an independent predictor of long-term survival. We conclude that for patients who undergo oesophagectomy alone as a treatment for oesophageal cancer, the prognostic importance of CRM involvement is unclear. However, for patients who undergo preoperative chemotherapy prior to surgery, there does appear to be emerging evidence supporting the concept that CRM involvement is an independent predictor of poor long-term outcome.

Entities:  

Mesh:

Year:  2010        PMID: 20736225     DOI: 10.1510/icvts.2010.236778

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  3 in total

1.  Long-term outcomes of extended proximal gastrectomy for oesophagogastric junctional tumours.

Authors:  Omar Khan; Steven Goh; Ben Byrne; Shaw Somers; Stuart Mercer; Simon Toh
Journal:  World J Surg       Date:  2011-10       Impact factor: 3.352

2.  NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma.

Authors:  Somnath Mukherjee; Christopher N Hurt; Sarah Gwynne; Andrew Bateman; Simon Gollins; Ganesh Radhakrishna; Maria Hawkins; Jo Canham; Wyn Lewis; Heike I Grabsch; Ricky A Sharma; Wendy Wade; Rhydian Maggs; Bethan Tranter; Ashley Roberts; David Sebag-Montefiore; Timothy Maughan; Gareth Griffiths; Tom Crosby
Journal:  BMC Cancer       Date:  2015-02-12       Impact factor: 4.430

3.  Prognostic Value of the Circumferential Resection Margin in Esophageal Cancer Patients After Neoadjuvant Chemoradiotherapy.

Authors:  J B Hulshoff; Z Faiz; A Karrenbeld; G Kats-Ugurlu; J G M Burgerhof; J K Smit; J Th M Plukker
Journal:  Ann Surg Oncol       Date:  2015-08-28       Impact factor: 5.344

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.